User:Mr. Ibrahem/Ponatinib

Mr. Ibrahem/Ponatinib
Clinical data
Pronunciation	/poʊˈnætɪnɪb/ poh-NAT-i-nib; Iclusig: /aɪˈkluːsɪɡ/ eye-KLOO-sig
Trade names	Iclusig
Other names	AP24534
AHFS/Drugs.com	Monograph
MedlinePlus	a613029
License data	EU EMA: by INN; US DailyMed: Ponatinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth (tablets)
Drug class	Tyrosine-kinase inhibitor
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	Unknown
Protein binding	>99% (in vitro)
Metabolism	Liver (CYP3A4, 2C8, 2D6, 3A5)
Elimination half-life	12–66 hours
Excretion	Feces (87%), urine (5%)
Identifiers
	IUPAC name 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;
Chemical and physical data
Formula	C29H27F3N6O
Molar mass	532.571 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C;
	InChI InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39); Key:PHXJVRSECIGDHY-UHFFFAOYSA-N;

Ponatinib, sold under the brand name Iclusig, is a medication used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) which is Philadelphia chromosome–positive (Ph+).^[1] It is used when other treatments have failed.^[1] It is taken by mouth.^[1]

Common side effects include pneumonia, pancreatitis, fever, abdominal pain, heart attack, atrial fibrillation, low platelets, low neutrophils, stroke, kidney problems, and heart failure.^[3] Serious blood clots occur in arteries in about 25% of people and veins in about 5% of people.^[3] It is a tyrosine-kinase inhibitor which blocks Bcr-Abl.^[1]^[3]

Ponatinib was approved for medical use in the United States in 2012 and Europe in 2013.^[1]^[3] In the United Kingdom it costs the NHS about £5,100 per month.^[4] This amount in the United States is about 19,000 USD.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Ponatinib Monograph for Professionals". Drugs.com. Archived from the original on 6 March 2016. Retrieved 28 October 2021.
^ "Iclusig (ponatinib) Tablets, for Oral Use. Full Prescribing Information". ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street, Cambridge, MA 02139-4234. Archived from the original on 17 October 2018. Retrieved 2 October 2016.
^ ^a ^b ^c ^d ^e "Iclusig". Archived from the original on 13 August 2021. Retrieved 28 October 2021.
^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1041. ISBN 978-0857114105.
^ "Iclusig Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 28 October 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Ponatinib Monograph for Professionals". Drugs.com. Archived from the original on 6 March 2016. Retrieved 28 October 2021.

[PI-2] "Iclusig (ponatinib) Tablets, for Oral Use. Full Prescribing Information". ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street, Cambridge, MA 02139-4234. Archived from the original on 17 October 2018. Retrieved 2 October 2016.

[EPAR2021-3] "Iclusig". Archived from the original on 13 August 2021. Retrieved 28 October 2021.

[BNF81-4] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1041. ISBN 978-0857114105.

[5] "Iclusig Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 28 October 2021.

[1]

[2]

[3]

[4]

[5]